AI-enabled hematology and cytology analysis improves diagnostic speed, consistency, and workflow efficiency for veterinary clinics ANN ARBOR, MI / ACCESS Newswire / January 23, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company providing innovative point-of-care diagnostic and therapeutic solutions for equine and companion animals, today announced the integration of advanced artificial intelligence (AI) interpretation capabilities into its TRUVIEW® AI digital microscopy system. The AI enhancement expands functionality of the TRUVIEW system by enabling automated interpretation of hematology blood films, with skin and ear cytology to follow shortly.

TORONTO, ON / ACCESS Newswire / January 20, 2026 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) Caldwell today announced a three-year sponsorship with Deloitte Canada on Canada's Outstanding CEO of the Year® Award Program. Deloitte Canada will become the presenting sponsor of the program, with Fatima Laher, Deputy Chair of the Board of Deloitte Canada and Chile, assuming the role of the CEO of the Year Advisory Board Chair.

At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510; [95% CI, 0.294-0.887]) compared to KEYTRUDA alone The Companies plan to present further data from follow up analyses of the study's primary and secondary endpoints at a future medical conference Eight Phase 2 and Phase 3 clinical trials underway across multiple tumor types including melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma CAMBRIDGE, MA AND RAHWAY, NJ / ACCESS Newswire / January 20, 2026 / Moderna, Inc. (NASDAQ:MRNA) and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced median five-year follow-up data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, evaluating intismeran autogene (mRNA-4157 or V940), an investigational mRNA-based individualized neoantigen therapy (INT), in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with high-risk melanoma (stage III/IV) following complete resection. In this pre-planned analysis, adjuvant treatment with intismeran autogene in combination with KEYTRUDA continued to demonstrate sustained and clinically meaningful improvement in the study's primary endpoint, recurrence-free survival (RFS), reducing the risk of recurrence or death by 49% (HR=0.510; [95% CI, 0.294-0.887]; one-sided nominal p=0.0075) compared to KEYTRUDA alone.

Ryder (R) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Ryder System is rated a buy due to secular private fleet outsourcing growth, technology differentiation, and inflation-protected contracts. R benefits from defensive, contract-backed revenue (~90% contractual, 3–7 year terms) and strong ROE (~17%) even in a freight downturn. Technology platforms like RyderShare and RyderGyde drive customer stickiness and structural growth, with one-third of new wins attributed to tech.

VANCOUVER, BC / ACCESS Newswire / January 14, 2026 / Global Education Communities Corp. ("GECC" or the "Company") (TSX:GEC)(OTCQB:GECSF) is pleased to announce that the City of Vancouver has approved the rezoning and density increase for GEC® Langara. The approval transitions the site from a single-house residential designation to that of a 26-storey rental apartment tower.

Strengthening its position in embodied AI data for Vision-Language-Action (VLA) models as the global AI robotics market surges toward $125 billion by 2030 LOS ANGELES, CA / ACCESS Newswire / January 14, 2026 / Nexscient, Inc. (OTCQB:NXNT), a leading innovator in artificial intelligence (AI) applications and intelligent enterprise solutions, today announced the execution of a definitive Stock Purchase Agreement to acquire Flipside Digital Content Company, Inc. ("Flipside AI"), a Philippines-based leader in AI data engineering. Under the terms of the agreement, Nexscient will acquire 100% of Flipside's issued and outstanding shares through a multi-step reorganization for an aggregate consideration of approximately $6.20 million, consisting of $600,000 in cash, a $450,000 convertible promissory note, and 6,846,000 shares of Nexscient's restricted common stock.

Earth Week Miami® 2026 The ECO Channel Partners with Industry Leaders to Accelerate Green Tech Innovation MIAMI, FL / ACCESS Newswire / January 12, 2026 / TGI Solar Power Group Inc. (OTC PINK:TSPG), subsidiary Advent Buzz, is pleased to announce a new strategic partnership with The ECO Channel, Inc., to expand the digital footprint and merchandise reach of its flagship initiative, Earth Week Miami®. Under the newly signed Letter of Agreement, dated January 8, 2026, Advent Buzz will provide targeted digital marketing and merchandising sales support.

R kicks off 2026 with the Truck Service Depot acquisition, expanding its retail mobile maintenance business, Torque by Ryder's footprint across Georgia and key freight corridors.

Toronto, Ontario--(Newsfile Corp. - December 23, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses is pleased to announce that it has successfully closed a non-brokered private placement offering ("Offering") of units ("Units"). On closing, the Corporation issued an aggregate of 7,850,882 Units at a price of $CAN 0.17 per Unit for aggregate gross proceeds of approximately $CAN 1,334,650.